Kornimate/medical-research-clean huggingface dataset:
nutritional therapy for delirium in elderly hospitalized subjects

Conditions: Subacute Delirium

Summary: the investigators have developed a proprietary blend of amino acids that they think will help to prevent or reduce the severity of delirium in older adults (60 years and older) who are hospitalized for certain infections. in this study, up to 45 people will be enrolled.15 will be asked to drink this blend twice a day for up to 4 days, and 15 will receive standard treatment in the hospital for the same time period. the other 15 subjects will be non-delirious control subjects who do not consume any study products.

this will be an interventional pilot study to determine the effectiveness of a specific amino acid supplement developed by the investigators versus standard treatment in mitigating delirium in geriatric patients hospitalized at uams for certain infections. up to 30 delirious and 15 non-delirious subjects (aged 60 years and older) of any gender or ethnicity will be enrolled (45 subjects maximum). fifteen patients with delirium will be asked to drink this blend twice a day for up to 4 days, and 15 patients with delirium will receive standard treatment in the hospital for the same time period. the other 15 subjects will be non-delirious control subjects who do not consume any study products. all subjects will undergo 2-5 blood draws and 3-7 cognitive assessments while they are admitted to the hospital, depending on study group assignment and discharge date.

Eligibility criteria:
inclusion criteria: delirious cohort 1. aged 60 years and older. 2. documented presence of either delirium, acute confusion, or altered mental status in medical record. 3. currently hospitalized with a diagnosis of one of the following: 1. sepsis/septicemia 2. pneumonia 3. urinary tract infection 4. clostridium-difficile infection 5. other bone or tissue infection 6. fever of unknown origin inclusion criteria: non-delirious cohort 1. aged 60 years and older. 2. current diagnosis of one of the following: 1. sepsis/septicemia 2. pneumonia 3. urinary tract infection 4. clostridium-difficile infection 5. other bone or tissue infection 6. fever of unknown origin exclusion criteria: all subjects 1. chronic kidney disease (egfr \<30). 2. admitted to the hospital for major psychiatric illness. 3. major psychiatric illness not controlled by medication/treatment. 4. delirium etiology of drug overdose or alcohol withdrawal. 5. major surgery within the past five days. 6. known or suspected covid-19 positive. 7. continuous feeding tube
sr34006 compared to vitamin k antagonist (vka) in the treatment of pulmonary embolism

Conditions: Pulmonary Embolism

Summary: patients who have a pulmonary embolism (blood clot in the lung) will be treated in this study. the purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood-thinning) drug, sr34006, with the standard way of treating a pulmonary embolism. the standard treatment includes injections or infusions of an anticoagulant drug, (lmw)heparin, for about a week followed by anticoagulant tablets (warfarin or acenocoumarol) which are taken by mouth. assignment to either sr34006 or (lmw)heparin plus warfarin or acenocoumarol will be purely by chance and will be known by both patients and their doctors.


Eligibility criteria:
inclusion criteria: * confirmed acute symptomatic pulmonary embolism (pe) with or without concomitant deep vein thrombosis (dvt) * written informed consent exclusion criteria: * legal lower age limitations (country specific) * thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of pe * other indication for vka than pe/dvt * more than 36 hours pre-randomization treatment with therapeutic dosages of (lmw)heparin or initiation of vka treatment prior to randomization * participation in another pharmacotherapeutic study within the prior 30 days * creatinine clearance \<10 ml/min, severe hepatic disease, or bacterial endocarditis * life expectancy \<3 months * active bleeding or high risk for bleeding * uncontrolled hypertension: systolic blood pressure \>180 mm hg or diastolic blood pressure \>110 mm hg * pregnancy or childbearing potential without proper contraceptive measures or women who are breastfeeding * any other contraindication listed in the labeling of warfarin, acenocoumarol, unfractionated heparin, enoxaparin, or tinzaparin
phase ii study of novantrone(r) (mitoxantrone) and etoposide in patients with hiv associated large cell and immunoblastic lymphomas

Conditions: Lymphoma, Non-Hodgkin; HIV Infections

Summary: to determine the efficacy and toxicity of the combination of mitoxantrone hydrochloride ( novantrone ) and etoposide in the treatment of patients with hiv associated lymphomas.


Eligibility criteria:
inclusion criteria patients must have the following: * positive hiv antibody, positive hiv culture or antigen capture, or prior diagnosis of aids by the cdc criteria. * diagnosis by pathological examination of large cell or immunoblastic lymphoma within measurable or evaluable disease. * pneumocystis carinii pneumonia (pcp) prophylaxis during the course of the study. * signed written informed consent. exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * acute intercurrent opportunistic infection, such as pneumocystis carinii pneumonia (pcp) diagnosed within 3 weeks. * stage ie central nervous system lymphomas. patients with the following are excluded: * more than one previous treatment for lymphoma. * acute intercurrent opportunistic infection, such as pneumocystis carinii pneumonia (pcp) diagnosed within 3 weeks. * conditions that preclude obtaining an informed consent. * not accessible for scheduled treatment visits or follow-up. * stage ie central nervous system (cns) lymphomas. prior medication: excluded within 2 weeks of study entry: * zidovudine. * excluded: * doxorubicin dosing = or \> 300 mg/m2. prior treatment: excluded: * received more than one previous treatment regimen for lymphoma. required: * prophylactic treatment for pneumocystis carinii pneumonia (pcp) prophylaxis.

Keywords: mitoxantrone lymphoma, large-cell etoposide acquired immunodeficiency syndrome
interventions for postoperative delirium: biomarker-3

Conditions: Delirium

Summary: the ipod-b3 study aims to characterize the relationship between premorbid brain activity and postoperative delirium in patients undergoing major surgery. this is a expansion of the neurovision bolt-on study, nct01980511.


Eligibility criteria:
inclusion criteria: * cohort 1: age ≥65 years * cohort 2: age ≥60 years * anticipated length of hospital stay of at least 2 days after surgery that occurs under general or neuraxial anesthesia * written informed consent for potential participation prior to surgery exclusion criteria: * contraindication to eeg * unable or unwilling to attend the follow-up appointments * documented history of dementia * deemed incapable of providing consent by surgical team * residing in a nursing home * undergoing intracranial surgery * unable to complete neurocognitive testing due to language, vision or hearing impairment * unable to communicate with the research staff due to language barriers * for optional mri portion of the study: contraindication to mri (e.g., implanted devices not safe for mri studies, claustrophobia, unable to lie flat or still)
multimodal assesment of alzheimer patients

Conditions: Mild Cognitive Impairment; Alzheimer Disease, Late Onset; Cognitive Impairment; Dementia

Summary: the goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (mci) and alzheimer's disease (ad). the main questions the study aims to answer are: 1. what findings can be used to earlier detect patients that will develop alzheimers? 2. which differences are seen between healthy and cognitively impaired patients? 3. which differences are seen between patients with alzheimers disease? participants will undergo: * cognitive tests * magnetic resonance imaging (mri) * electroencephalography (eeg) * blood sample collection * fecal sample collection * a randomized group will undergo polysomnography analysis.

the projects aims to map brain changes in patients with mild cognitive impairment (mci) and alzheimer's disease (ad) by combining different assesment modalities. in the mri, researchers will get the opportunity to analyse both structural and functional brain changes. in the eeg, changes in elctrical activites will be measured. the blood samples allow researchers to analyse specific dementia and inflammation proteins, while fecal speciments can be used to assess bacterial composition. additionally, the cognitive testing allow to assess the specific part of cognitive function which is affected.

Eligibility criteria:
inclusion criteria: * mci and ad according to relevant icd-criterias. * control cohort is age and gender matched with other cohorts. exclusion criteria: * uneligibility for any of the planned neuroimagery devices (mri, eeg) * ad diagnosis before the age of 65 (early-onset ad). * brain tumor * traumtic head injury * earlier neurosurgery * other neyrodegenerative diseases (i.e parkinson and als) * diseases related to inflammation and auto-immunity (i.e ms)

Keywords: alzheimer disease (ad) mild cognitive impairment (mci) brain diseases nervous system disorders neurodegenerative diseases dementia cognitive impairment
effects of judo- specific injury prevention exercise programme judo athletes

Conditions: Sports Physical Therapy

Summary: the study aimed to determine whether the judo-specific injury prevention exercise program had a significant positive effect on the performance of recreational judo athletes, with a particular focus on those employing the ippon technique.

the significant results obtained from our study are considered to be originated from the duration, scope, frequency, severity and content of training.

Eligibility criteria:
inclusion criteria: * recreational judo athletes aged 18 to 35 years. * participants with at least one year of regular participation in recreational judo athletes with no existing major musculoskeletal injuries or chronic health conditions that would limit their ability to participate in the prescribed exercise program. * participants willing to provide informed consent and commit to the duration of the study, including regular attendance at training sessions and data collection activities. * athletes engaging in judo training at least twice a week. exclusion criteria: * athletes below 18 or above 35 years of age. * novice judo practitioners with less than one year of regular training. * individuals with a history of significant musculoskeletal injuries in the past six months or chronic conditions affecting their ability to participate fully. * participants unwilling or unable to provide informed consent or commit to the study requirements. * athletes participating in judo training less than twice a week, as they may not represent a group with sufficient exposure to the injury prevention program. * professional or highly competitive judo athletes, as their training regimens and performance levels may differ significantly from recreational athletes.

Keywords: judo sports injury martial art agility plyometric exercise strength ippon
nasr fascial closure: a novel device for fascial closure in laparoscopic surgery

Conditions: Cholecystolithiasis

Summary: the study will investigate the efficacy and safety of a new fascial closure device "nasr fascial closure device" compared to the karl storz berci fascial closure device 26173am.


Eligibility criteria:
inclusion criteria: * age \> 18 * eligible for laparoscopic cholecystectomy exclusion criteria: * refused to participate

Keywords: laparoscopic removal
contributions to hypertension with androgen deprivation therapy

Conditions: Androgen Deprivation Therapy; Prostate Cancer; Hypertension; Autonomic Dysfunction; Renal Disease

Summary: this study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (adt) to treat prostate cancer. prostate cancer is the most common non-skin cancer in men, affecting approximately 1 in 8 american men and its primary treatment is through the use of adt. however, adt increases the likelihood of developing heart disease including high blood pressure. this study will determine if dysfunction of the nervous system and/or kidneys occurs in men undergoing adt, as these systems play a significant role in control of blood pressure. the results from this study will help us understand the ways in which adt contributes to heart disease and help us develop therapies to prevent heart disease in prostate cancer survivors.


Eligibility criteria:
inclusion criteria: * -age 40+ years; * resting blood pressure \<140/90 mmhg; * fasted blood glucose \<126 mg/dl; * testosterone ≥400 ng/dl; * sedentary to recreationally active; * nonsmokers; * healthy as determined by medical history, physical exam, blood and urine chemistries and resting and exercise ecg during a physician supervised graded exercise treadmill test or recent diagnosis of non-metastatic prostate cancer with plans to undergo androgen deprivation therapy; * psa \<4.00 ng/dl if in the non-cancer group; * gleason score ≤7 if in the prostate cancer group; * no use of medications that might influence cardiovascular function (e.g., antihypertensives, lipid-lowering medications); * willing and able to be on gnrhagonist and ar inhibitor; * not taking antioxidant vitamins, corticosteroids, or anti-inflammatory medications, or willing to stop use for four weeks prior to the start of the study; * not using exogenous sex hormones for at least one year exclusion criteria: * -acute liver disease; * chronic kidney disease, serum creatinine \>1.3 mg/dl, macroalbuminuria \>300 mg/g of proteinuria * pre-existing or active cardiac, renal or hepatic disease, epilepsy or other seizure disorder; * diabetes, active or chronic infection, disease that affects the nervous system; * gleason score ≥8; * thyroid dysfunction, defined as ultrasensitive tsh \ 5.0 mu/l, volunteers with abnormal tsh values will be re-considered for participation after follow-up evaluation by the pcp with initiation or adjustment of thyroid hormone replacement; * tobacco use within the previous 12 months
study of the pathogenesis of porphyria cutanea tarda

Conditions: Porphyria Cutanea Tarda

Summary: objectives: i. determine the effect of standard treatments on various predisposing factors in patients with porphyria cutanea tarda (pct). ii. investigate alcohol history, smoking, liver dysfunction and its etiology, estrogen use, and family history of pct in these patients. iii. study the relationships of excess iron and the hemochromatosis gene to pct, including clinical features and risk of recurrence in these patients. iv. assess hepatitis c virus infections in these patients. v. assess vitamin c levels in these patients before and after treatment. vi. assess dietary habits in these patients. vii. assess activity of cytochrome p450 enzymes (cyp) in vivo in these patients. viii. study polymorphic genes for enzymes that metabolize foreign chemicals, including cyp enzymes and glutathione transferases in these patients.

protocol outline: patients undergo a complete medical evaluation and documentation of porphyria cutanea tarda (pct) including history, physical examination, standard clinical laboratory tests and porphyrin studies. alcohol history, smoking, liver dysfunction and its etiology, estrogen use, and family history of pct are investigated and recorded. patients complete a questionnaire to assess intake of vitamin c and other nutrients. iron status is assessed by serum ferritin, fe and fe binding capacity, and by the number of phlebotomies needed to reduce ferritin to the target level. a blood sample is tested for the hemochromatosis (hc) gene to determine whether each patient has 0, 1, or 2 copies of the hc mutation. serum hepatitis c virus (hcv) antibody and hcv rna are measured. standard liver function tests and liver biopsy are done if clinically indicated. a fasting blood level of ascorbic acid is obtained. blood clearance of caffeine and antipyrine, and urinary excretion of caffeine and chlorzoxazone metabolites are determined by breath tests or measurements in blood or saliva. genotyping for polymorphic genes for enzymes that metabolize foreign chemicals, including cytochrome p450 enzymes (cyp) and glutathione transferases are completed. following completion of the above studies, patients undergo individualized standard treatment either by serial phlebotomies or low dose chloroquine. patients with hcv are also treated with interferon alfa-2b. patients are followed after treatment, at which time initial studies are repeated.

Eligibility criteria:
* well documented sporadic (type i) or familial (type ii) porphyria cutanea tarda: increased plasma porphyrins (fluorescence maximum at neutral ph near 617 nm) increased urinary porphyrins (consisting mostly of uroporphyrin and heptacarboxylporphyrin) increased isocoproporphyrins in feces * no other type of porphyria

Keywords: inborn errors of metabolism porphyria porphyria cutanea tarda rare disease
robotic-assisted therapy with bilateral practice improves task and motor performance of the upper extremity for chronic stroke patients

Conditions: Stroke Rehabilitation

Summary: task-specific repetitive training, an usual care in occupational therapy practice, and robotic-aided rehabilitation with bilateral practice to improve limb's movement control has been popularised; however the difference in treatment effects between this two therapeutic strategies has been rarely described. the aim of the study was to compare the efficacy of robotic-assisted therapy with bilateral practice (rtbp) and usual care on task and motor performance for chronic stroke patients.


Eligibility criteria:
inclusion criteria: * chronic stroke patients with unilateral cerebral infarction or hemorrhage and whose disease duration was more than six months following stroke * no evidence of any other cerebral pathology in study screening ct scan * a score for the fugl-meyer upper extremity motor assessment ranging from 23-53 corresponding to poor to notable arm-hand capacity * pre stroke ability to speak the chinese * without any other possible somatic sensory impairment, no major cognitive-perceptual deficit based on the results of selective neuropsychological tests, such as the mini-mental state examination (mmse) and lowenstein occupational therapy cognitive assessment (lotca) * premorbid right-handedness exclusion criteria: * less than six months following stroke * ct shows multiple cerebral infarction or hemorrhage * whose comprehension skills were insufficient to understand instructions * individuals whose score of mmse was lower than 24 or sub-item scores of visual perception, spatial perception, praxis, and visuomotor organization in lotca was lower than 8, 6, 6, and 14, respectively * premorbid left-handedness

Keywords: stroke robotic-assisted therapy bilateral practice task-specific training rehabilitation
two di̇fferent electrosurgery devices as monopolar hooc and plasmakinetic bipolar spatula effectiveness during colpotomy

Conditions: Uterine Fibroid; Ovary Cyst; Endometrial Hyperplasia; Cervical Dysplasia

Summary: we decided to compare two different electrosurgery devi̇ces to provide colpotomy. one of them i̇s monopolar hooc, the other devi̇ce i̇s plasmaki̇neti̇c bi̇polar spatula. we wi̇ll randomi̇se pati̇ents fi̇rstly then compare the results such, vagi̇nal dehi̇ssens, colpotomy durati̇on, amount of mist during colpotomy, amount of bleedi̇ng.

colpotomy is a process during total laparoscopic hysterectomy. we can use ei̇ther electrosurgery instruments to provide colpotomy. in our trial we wi̇ll randomi̇se pati̇ents fi̇rstly then compare the results such, vagi̇nal dehi̇ssens, colpotomy durati̇on, amount of mist during colpotomy, amount of bleedi̇ng.

Eligibility criteria:
inclusion criteria: * appropiate for total laparoscopic hysterectomy exclusion criteria: * malignancy
delivering treatment in dui programs to reduce alcohol-related disparities

Conditions: Alcohol Abuse

Summary: the current study evaluates the efficacy of cognitive behavioral therapy (cbt) in dui programs for individuals with a first-time offense. investigators will utilize a two-group randomized design where individuals enrolled in a dui program with a first-time conviction will be randomized to cognitive behavioral therapy (cbt; n=150) or usual care (uc; n=150). participants will be assessed at baseline, immediately post-treatment, and 6-months post-treatment. recidivism data will also be collected using administrative data two years post-treatment.

enormous unmet needs for alcohol treatment exist among individuals convicted of driving under the influence (dui) since up to 43% recidivate and 67% meet criteria for alcohol dependence. investigators will test whether delivering a cognitive behavioral treatment (cbt) for alcohol use disorders (auds) as part of a mandated dui program improves health outcomes, and reduces alcohol use, alcohol-related problems and injuries, and dui recidivism compared to usual care. the study has the potential to promote the public welfare by providing treatment to individuals with a dui conviction, while focusing on latinos, who are disproportionately less likely to access treatment and more likely to be arrested for a dui, to have higher rates of recidivism, and to die in alcohol-related crashes than their white counterparts. the study is innovative because it would be the first to address effectiveness of treatment for auds embedded within a dui program. investigators will conduct a randomized trial of a 9-session group-based cbt (n=150) as compared to group-based usual care (uc; n=150) immediately after and 6 months after the end of treatment. short-term outcomes include alcohol use (rates of heavy drinking, percent days abstinent), alcohol use-related self-efficacy, and intent to drink and drive. investigators will also examine whether race/ethnicity, gender, acculturation, and alcohol situational norms predict our primary treatment outcomes (rates of heavy drinking, percent days abstinent) and dui recidivism (alcohol-related violations).

Eligibility criteria:
inclusion criteria: * meets criteria for at-risk drinking, * 21 years+, * english speaking, * current client in 3-month dui program exclusion criteria: * under 21, * does not speak english, * does not meet criteria for at-risk drinking
auto-pap therapy for improved fetal growth

Conditions: Obstructive Sleep Apnea; Pregnancy

Summary: the purpose of this study is to see whether the presence of night-time breathing disturbances ("sleep-disordered breathing") in pregnant women is related to fetal growth patterns. the hypothesis is that fetal growth slows in the 3rd trimester in women with sleep-disordered breathing. use of a nighttime breathing therapy called auto-pap could minimize the slowing in fetal growth.


Eligibility criteria:
inclusion criteria: * at least 18 years old; * no more than 20 weeks pregnant; * pregnant with one baby; * found to have sleep-disordered breathing as measured by a sleep study. if you are found to have severe sleep apnea on the sleep study you will be referred for clinical care instead of participating in the study. exclusion criteria: * more than 20 weeks pregnant; * pregnant with twins, triplets, or more babies; * a current smoker, drink alcohol, or use recreational drugs; * currently using positive-airway pressure therapy for treatment of obstructive sleep apnea; * diagnosed with certain conditions such as bullous lung disease, a bypassed upper airway, pneumothorax (collapsed lung), pneumocephalus (leak of cerebrospinal fluid, the fluid that the brain and spine float in), if you have had recent trauma, or recent nasal surgery.